Taysha receives FDA feedback on TSHA-120 GAN; sets Rett syndrome milestones for 2023

Taysha Gene Therapies, Inc.

FDA acknowledged MFM32 as acceptable endpoint; recommended double-blind placebo-controlled design for TSHA-120 BLA.
Dosing of first adult Rett patient with TSHA-102 expected H1 2023; initial clinical data also in H1 2023.
CTA submission to UK MHRA for pediatric Rett syndrome expected mid-2023; IND to FDA planned H2 2023.
Operational, structural and personnel changes implemented following business review to enhance execution.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.